In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Indaptus Therapeutics (INDP – Research Report), with a price target of $4.00. The company’s shares opened today at $2.19.
According to TipRanks, McCarthy is an analyst with an average return of -30.7% and a 20.68% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Daré Bioscience, SELLAS Life Sciences Group, and Achieve Life Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Indaptus Therapeutics with a $8.00 average price target, implying a 265.30% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
INDP market cap is currently $18.57M and has a P/E ratio of -1.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
Read More on INDP:
- Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
- Indaptus Therapeutics announces opening of next cohort in trial of Decoy20
- Indaptus Therapeutics appoints Waltzman as Chief Medical Officer
- Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer
